Hymont-LC Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a potent third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby alleviating symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), reducing inflammation, bronchoconstriction, and mucus secretion associated with allergic responses. The synergistic action of these agents provides comprehensive relief from both immediate and late-phase allergic reactions. Hymont-LC is particularly effective in patients with concomitant asthma and allergic rhinitis, improving respiratory function and quality of life. The tablet is administered orally, once daily, preferably in the evening, with or without food. It is generally well tolerated; common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision during pregnancy and lactation. Hymont-LC Tablet offers an effective therapeutic option for controlling allergic symptoms and preventing exacerbations, enhancing patient compliance through its convenient fixed-dose combination.